Sentences with phrase «of lung cancer research»

Dr. Shepherd has been recognized for her many contributions in the field of lung cancer research.

asks Paul Bunn Jr., MD, FASCO, distinguished professor at the University of Colorado Cancer Center and James Dudley Professor of Lung Cancer Research at the University of Colorado School of Medicine.

Not exact matches

Because of lung cancer's reputation as a self - induced illness and its low survival rate, it rarely attracts big research money.

She spoke at Genentech, a cancer research firm, exchanged e-mails with half a dozen other cancer patients nationwide and was interviewed on NPR as a voice of nonsmoker lung - cancer sufferers.

This appeared to be confirmed by further research in 1954, prompting the government to issue its first warning of the link between lung cancer and smoking.

Smoking in cars can expose children's lungs to levels of carcinogens and toxins at rates 10 times higher than when smoking was permitted in bars, added Dr. Mark Travers, a research scientist in the Division of Cancer Prevention and Population Sciences at Roswell.

«Our study suggests that epigenetic changes to cells treated with cigarette smoke sensitize airway cells to genetic mutations known to cause lung cancers,» says Stephen Baylin, M.D., the Virginia and D.K. Ludwig Professor for Cancer Research and professor of oncology at the Johns Hopkins Kimmel Cancer Center.

Scientists from Moffitt reported in the Jan. 19 online edition of Cancer Research that nicotine induces the metastatic spread of lung cancer cells by stimulating a protein called beta - arrestiCancer Research that nicotine induces the metastatic spread of lung cancer cells by stimulating a protein called beta - arresticancer cells by stimulating a protein called beta - arrestin - 1.

After 20 years of research and almost as many years fighting industry groups in court for control of their data, government scientists can finally publish two papers showing that underground miners exposed to diesel fumes have a threefold increased risk for contracting lung cancer.

Delegates included those interested in all aspects of lung cancer, including surgeons, medical oncologists, radiation oncologists, pulmonologists, radiologists, pathologists, epidemiologists, basic research scientists, with special sessions for nurses, allied health professionals and advocacy members.

If hypofractionated radiation with curative intent can reduce the treatment time for lung cancer patients by half with no greater toxicity, and with equivalent — if not better — tumor control and survival outcomes, this research could result in a change in the paradigm of how a large subset of locally advanced NSCLC patients are treated.»

The research was published in the Jan. 18 issue of Molecular Carcinogenesis, which focused on recent advances in lung cancer.

While pursuing her project on how environmental contaminants and oxidative stress cause lung cancer, Gelhaus complemented her postdoctoral training by spending some time with other PIs at Penn. «She has worked hard to develop skills that are independent of those available in my own laboratory while working on a project that is central to my research program,» Blair writes in an e-mail to Science Careers.

«We urgently need new treatments for lung cancer patients, and this research suggests we can boost the effectiveness of an existing drug, rather than switch to another new expensive treatment.

The trial also recorded fewer cases of lung cancer in those on the treatment, consistent with basic research findings hinting that the same inflammatory pathway may initiate or spur tumor growth.

Until now, EGFR inhibitors have only been effective at treating the 10 to 15 percent of non-small cell lung cancers that have a variant of EGFR, but the two - drug combo could potentially work for all non-small cell lung cancers, explained Dr. John Minna, Director of the Hamon Center for Therapeutic Oncology Research and Professor of Internal Medicine and Pharmacology.

Called the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) and funded by the drug giant Novartis, the trial also found fewer cases of lung cancer in those on the treatment, rekindling basic research findings hinting that the same inflammatory pathway may initiate or spur the growth of such tumors.

The research was funded by the National Heart, Lung, and Blood Institute of the National Institutes of Health and the National Cancer Institute.

A drug approved by the Food and Drug Administration (FDA) for melanoma in combination with a common cholesterol - lowering drug may show promise in controlling cancer growth in patients with non-small cell lung cancer (NSCLC), according to new research from the Icahn School of Medicine at Mount Sinai.

Italian researches have demonstrated a better way of determining the aggressiveness of tumors in patients with advanced non-small cell lung cancer (NSCLC).

Researchers at the Menzies Centre for Population Health Research in Hobart have found that in Tasmania between 1983 and 1992, there were almost twice as many lung cancer cases among women aged between 25 and 44 years as in men of the same age.

Terry Dwyer, director of the centre, says that more research will be needed before the jump in lung cancer in women under 45 can be blamed primarily on smoking.

New research shows that microRNA - 486 is a potent tumor - suppressor molecule in lung cancer, and that the it helps regulate the proliferation and migration of lung - cancer cells, and the induction of programmed cell death, or apoptosis, in those cells.

Research from McMaster University has identified new regulators of brain metastases in patients with lung cancer.

«If you look at a set of lung cancer patients, like we did in the paper, who develop brain metastases, they all have those two genes in their primary lung cancer,» said Sheila Singh, the study's supervisor, associate professor at the Michael G. DeGroote School of Medicine, scientist with the Stem Cell and Cancer Research Institute at McMaster University and neurosurgeon at McMaster Children's Hoscancer patients, like we did in the paper, who develop brain metastases, they all have those two genes in their primary lung cancer,» said Sheila Singh, the study's supervisor, associate professor at the Michael G. DeGroote School of Medicine, scientist with the Stem Cell and Cancer Research Institute at McMaster University and neurosurgeon at McMaster Children's Hoscancer,» said Sheila Singh, the study's supervisor, associate professor at the Michael G. DeGroote School of Medicine, scientist with the Stem Cell and Cancer Research Institute at McMaster University and neurosurgeon at McMaster Children's HosCancer Research Institute at McMaster University and neurosurgeon at McMaster Children's Hospital.

The research, presented at the European Respiratory Society (ERS) International Congress in Munich, suggests that testing the temperature of breath could be a simple and noninvasive method to either confirm or reject the presence of lung cancer.

The research team accounted for the impact of smoking among the participants, since people who smoke are more likely to get periodontal disease, and smoking raises the risk of lung and colon cancers.

Researchers from the University of Portsmouth's Brain Tumour Research Centre of Excellence have identified molecules which are responsible for metastatic lung cancer cells binding to blood vessels in the brain.

Seemingly healthy cells may in fact hide clues that lung cancer will later develop, according to a study led by researchers at The University of Texas MD Anderson Cancer Center The research is published online in the Journal of the National Cancer Instcancer will later develop, according to a study led by researchers at The University of Texas MD Anderson Cancer Center The research is published online in the Journal of the National Cancer InstCancer Center The research is published online in the Journal of the National Cancer InstCancer Institute.

What's really impressive about Babar's accomplishment is that he did the work for both papers — one on the role of a population of stem cells in lung cancer development (published in Cell) the other on gene expression in group A Streptococcus (published in PNAS)-- as a participant in summer undergraduate research programs.

To investigate why checkpoint inhibitors so often stop working, Velculescu; Valsamo Anagnostou, M.D., Ph.D., instructor of oncology at the Johns Hopkins University School of Medicine; Kellie N. Smith, Ph.D., a cancer immunology research associate at the Johns Hopkins University School of Medicine; and their colleagues at the Bloomberg ~ Kimmel Institute for Cancer Immunotherapy studied tumors of four patients with non-small cell lung cancer and one patient with head and neck cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-cancer immunology research associate at the Johns Hopkins University School of Medicine; and their colleagues at the Bloomberg ~ Kimmel Institute for Cancer Immunotherapy studied tumors of four patients with non-small cell lung cancer and one patient with head and neck cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-Cancer Immunotherapy studied tumors of four patients with non-small cell lung cancer and one patient with head and neck cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-cancer and one patient with head and neck cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-CTLA4.

Dr. Timmerman, who holds the Effie Marie Cain Distinguished Chair in Cancer Therapy Research, has championed the use of SABR globally and has served as the lead investigator in several national trials designed to evaluate the efficacy and safety of SABR to treat cancer in the lung, liver, spine, and proCancer Therapy Research, has championed the use of SABR globally and has served as the lead investigator in several national trials designed to evaluate the efficacy and safety of SABR to treat cancer in the lung, liver, spine, and procancer in the lung, liver, spine, and prostate.

A lung cancer diagnosis appears to put patients at the greatest risk of suicide when compared to the most common types of non-skin cancers, according to new research presented at the ATS 2017 International Conference.

Scientists from the Cancer Research UK Manchester Institute, based at The University of Manchester and part of the Manchester Cancer Research Centre, teamed up with experts at AstraZeneca, as part of a collaboration agreed in 2010, to test a drug — known as AZD3965 — on small cell lung cancer Cancer Research UK Manchester Institute, based at The University of Manchester and part of the Manchester Cancer Research Centre, teamed up with experts at AstraZeneca, as part of a collaboration agreed in 2010, to test a drug — known as AZD3965 — on small cell lung cancer Cancer Research Centre, teamed up with experts at AstraZeneca, as part of a collaboration agreed in 2010, to test a drug — known as AZD3965 — on small cell lung cancer cancer cells.

The treatment is promising enough that research teams around the world are developing similar stem cell therapies that can target and eradicate cancers of the prostate, lung, breast, skin and other tissues.

The stem cells that proliferate the most in response to damage caused by cigarette smoke repair their DNA using a process prone to errors, setting the stage for lung cancer, according to a study publishing January 26, 2017 in the open - access journal PLOS Biology by Marie - Liesse Asselin - Labat and her team of the Walter and Eliza hall Institute of Medical Research, Australia.

The article, titled «Entinostat Neutralizes Myeloid Derived Suppressor Cells and Enhances the Antitumor Effect of PD - 1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma,» was published in Clinical Cancer Research and is available online.

The quest to improve survival of children with a high - risk brain tumor has led St. Jude Children's Research Hospital investigators to two drugs already used to treat adults with breast, pancreatic, lung and other cancers.

The research suggests that the genetic seeds of cancer can sit dormant in a person's lungs for decades, providing hope that the disease could be detected early.

The study's findings, published in the journal Cancer Research, are the first to use these combined agents as an immune stimulator and may have the potential to kill cancerous cells in solid tumors, including some of the most aggressive cancers that form in the lung and pancreas.

«Advances in lung cancer therapy require a greater understanding of the molecular origins of this deadly disease,» said last corresponding author Levantini, who is also a researcher at the Institute of Biomedical Technologies at the Italian National Research Council (ITB - CNR).

Recent research has shown that lung CT screening of smokers with smoking histories of at least 30 - pack years can lead to early detection of lung cancer and reduce deaths by 20 percent.

Anil Potti, M.D., Duke University School of Medicine: Based on the reports of investigations conducted by Duke University School of Medicine (Duke) and additional analysis conducted by ORI in its oversight review, ORI found that Dr. Anil Potti, former Associate Professor of Medicine, Duke, engaged in research misconduct in research supported by National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), grant R01 HL072208 and National Cancer Institute (NCI), NIH, grants R01 CA136530, R01 CA131049, K12 CA100639, R01 CA106520, and U54 CA112952.

Researchers from the Perelman School of Medicine at the University of Pennsylvania, along with the Institute for Health Research at Kaiser Permanente Colorado, Kaiser Permanente Hawaii, the Henry Ford Health System in Detroit, and Marshfield Clinic Health System in Wisconsin, have received a five - year, $ 15.5 million National Cancer Institute (NCI) grant to improve lung cancer screCancer Institute (NCI) grant to improve lung cancer screcancer screening.

Funding: NIH's National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Center for Advancing Translational Sciences (NCATS), National Cancer Institute (NCI), and National Human Genome Research Institute (NHGRI); and many other funding entities (see reference paper for the full list).

When a 2004 study by other researchers showed that eating foods containing beta - cryptoxanthin (BCX)-- a red pigment abundant in sweet red peppers, paprika, winter and butternut squash, oranges, and tangerines, among other foods — was associated with a lower risk of lung cancer in people who smoke, he made BCX a focus of his research.

The National Heart, Lung and Blood Institute of the U.S. Department of Health and Human Services, the National Cancer Institute and Wyeth - Ayerst Research Laboratories funded the study, which involved researchers at nine institutions and 15 WHI clinical - study sites nationwide.

The 19 NIH institutes, centers and offices contributing to the Knockout Mouse Project are: the NIH Office of Strategic Coordination / Common Fund; NCRR; the National Eye Institute; NHGRI; the National Institute of Allergy and Infectious Diseases; the National Heart, Lung and Blood Institute; the National Institute on Aging; the National Institute of Alcohol Abuse and Alcoholism; the National Institute of Arthritis and Musculoskeletal and Skin Diseases; the Eunice Kennedy Shriver National Institute of Child Health and Human Development; NIDCD; the National Institute of Dental and Craniofacial Research; the National Institute of Environmental Health Sciences; the National Institute of General Medical Sciences; the National Institute of Mental Health; the National Institute of Neurological Disorders and Stroke; the National Institute of Diabetes and Digestive and Kidney Diseases; the National Cancer Institute; and the Office of AIDS Research.

Commenting on the significance of the research, Dr Pilar Garrido, head of the Thoracic Tumour Section of the Medical Oncology Department at Ramón y Cajal University Hospital, Madrid, Spain, said: «Lung cancer is the most common cancer globally, but debate about the optimal screening strategy is ongoing and current selection criteria are based only on age and pack - years.

DENVER — A pre-competitive consortia of pharmaceutical, diagnostic companies and academic associations, including the International Association for the Study of Lung Cancer (IASLC), announced phase I results of the «BLUEPRINT PD - L1 IHC ASSAY COMPARISON PROJECT» at the Annual Meeting of the American Association for Cancer Research (AACR) on April 19.